BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16455513)

  • 1. [Monoclonal antibodies for lymphomas and leukemias in 2005].
    Peffault de Latour R; Robin M; Bay JO
    Bull Cancer; 2006 Jan; 93(1):107-18. PubMed ID: 16455513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody studies in B(non-T)-cell malignancies.
    Shimoyama M; Minato K; Tobinai K; Nagai M; Hirose M
    Jpn J Clin Oncol; 1983 Sep; 13(3):477-88. PubMed ID: 6417373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-targeted therapy for myeloid leukemia.
    Appelbaum FR
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):2-8. PubMed ID: 10530710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monoclonal antibodies in the treatment of lymphoma].
    Mounier N; Gisselbrecht C
    Rev Prat; 2002 May; 52(9):982-5. PubMed ID: 12063765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
    Countouriotis A; Moore TB; Sakamoto KM
    Stem Cells; 2002; 20(3):215-29. PubMed ID: 12004080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation against leukemias and lymphomas: a realistic future treatment?
    Mittal S; Marshall NA; Barker RN; Vickers MA
    Crit Rev Oncol Hematol; 2008 Feb; 65(2):101-8. PubMed ID: 17719232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
    Knox SJ; Goris ML; Trisler K; Negrin R; Davis T; Liles TM; Grillo-López A; Chinn P; Varns C; Ning SC; Fowler S; Deb N; Becker M; Marquez C; Levy R
    Clin Cancer Res; 1996 Mar; 2(3):457-70. PubMed ID: 9816191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody therapies in leukemias.
    Tallman MS
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):12-9. PubMed ID: 12447847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
    Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
    Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential.
    Epstein AL; Marder RJ; Winter JN; Stathopoulos E; Chen FM; Parker JW; Taylor CR
    Cancer Res; 1987 Feb; 47(3):830-40. PubMed ID: 3542194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab therapy in malignant lymphoma.
    Coiffier B
    Oncogene; 2007 May; 26(25):3603-13. PubMed ID: 17530014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
    Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant lymphomas].
    Yamaguchi Y; Usui N
    Gan To Kagaku Ryoho; 2009 May; 36(5):736-41. PubMed ID: 19461173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.